What motivated the pharmaceutical industry's early interest in high-fidelity, objective data?
Answer
Desire for more sensitive and objective measures of drug efficacy, especially in neurology/psychiatry.
A significant evolutionary step toward digital biomarkers was driven by specific unmet needs within the pharmaceutical research sector. In therapeutic areas like neurology and psychiatry, outcomes are often subjective, relying heavily on patient reporting, which can introduce variability. Researchers sought more sensitive and objective metrics to precisely evaluate how effective a new drug was actually working in the real world. This drive for high-fidelity, objective data collection provided a crucial impetus for developing technologies capable of passively monitoring changes in physiology and behavior linked to drug response.
Related Questions
What does the digital iteration of a biomarker swap for continuous data collection?What is the role of Digital Phenotyping regarding Digital Biomarkers?What must the underlying sensor and algorithm achieve for digital measurement to gain authority?What motivated the pharmaceutical industry's early interest in high-fidelity, objective data?What critical advancement moved digital measurements beyond descriptive purposes?When did the term "digital biomarker" appear to crystallize and see an explosion in literature?How does digital gait analysis using phone accelerometers enhance data collection over traditional methods?What inherent bias does a smartphone-derived digital biomarker introduce regarding access?Regarding tracing the concept's lineage, what did early research often focus on before formalizing the output?What characterizes a traditional biomarker compared to a dynamic digital one?